SCHEMBL4376100

SCHEMBL4376100

COc1ccn(Cc2cccc(F)c2)c(=O)c1C#N

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.69
KDM4E B2RXH2 4/20 0.60
ALDH1A1 P00352 4/20 0.60
KMT2A Q03164 3/20 0.60
PKM P14618 2/20 0.60
MEN1 O00255 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HPGD P15428 1/20 0.54
HSD17B10 Q99714 1/20 0.54
LMNA P02545 2/20 0.49
MAPT P10636 2/20 0.49
CYP2C9 P11712 1/20 0.49
PTGER3 P43115 1/20 0.45
GRM2 Q14416 2/20 0.45
POLB P06746 1/20 0.45
THRB P10828 1/20 0.45
MAPK1 P28482 1/20 0.44
GAA P10253 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382826 0.82 MAPK14 (1.00) MAPK14KDM4EALDH1A1KMT2APKM
SCHEMBL4376952 0.81 ALDH1A1 (0.64) MAPK14KDM4EALDH1A1KMT2APKM
SCHEMBL13635883 0.78 MAPK14 (0.85) MAPK14KDM4EALDH1A1KMT2APKM
SCHEMBL171698 0.75 LMNA (0.51) KDM4EALDH1A1LMNAMAPTCYP2C9
SCHEMBL27199572 0.75 LMNA (0.64) MAPK14KDM4EALDH1A1LMNAMAPT
SCHEMBL27199458 0.74 LMNA (0.59) MAPK14KDM4EALDH1A1LMNAMAPT
SCHEMBL10460796 0.74 LMNA (0.62) MAPK14KDM4EALDH1A1LMNAMAPT
SCHEMBL4392630 0.74 MAPK14 (0.68) MAPK14KDM4EALDH1A1KMT2APKM
SCHEMBL4490183 0.73 MAPK14 (0.80) MAPK14KDM4EALDH1A1KMT2APKM
SCHEMBL4382806 0.72 MAPK14 (0.62) MAPK14KDM4EALDH1A1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
EP-1490064-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE Pharmacia Corporation (US) 2004-12-29 EP disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885KDM4E 3869/4885ALDH1A1 787/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885KDM4E 3921/4885ALDH1A1 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.